恩瑞格在中国的价格

It is used to treat chronic iron overload caused by frequent blood transfusions (monthly administration of concentrated red blood cells ≥7 mL/kg) in patients with β-thalassemia older than 6 years old.

So, what is the price of Enrig in China?

According to Medical Travel, the price of Enrige after it was launched in China was relatively high, with a box costing about $2,000. A normal person weighing 60kg would cost more than 24,000$ to take Enrige for a month. It can be seen that it is difficult for ordinary families to accept this price and cannot afford it!

Fortunately, there are also foreign versions for everyone to choose from. Novartis from Switzerland imported Enrig from India. The specification is 400mg*30 tablets/box, and the price is about $700.

The specification of Enriga produced by Indian pharmaceutical factory is 500*30 tablets/box, and the price is about 500$. Due to the fluctuation of exchange rate, the price will be different. Please consult the medical companion tour for the specific price! 

Enrig was developed by Novartis and was the first oral iron chelator approved by the FDA for routine use in 2005. The FDA granted Enrig orphan drug status for the treatment of iron overload in non-transfusion-dependent thalassemia. It is currently on the market in more than 80 countries.

The oral suspension and dispersible tablets marketed in the United States are approved for the treatment of chronic iron overload due to transfusion in adult and pediatric patients 2 years and older and chronic iron overload in patients 10 years and older with non-transfusion-dependent thalassemia (NTDT) syndrome.

In 2012, Enrig was approved in the EU for the treatment of patients with chronic iron overload thalassemia aged 6 years and above due to frequent blood transfusions (hematocrit ≥7ml/kg/month). It was also approved for the treatment of chronic iron overload caused by blood transfusions when deferoxamine treatment is contraindicated or insufficient. In Japan, this product is approved for the treatment of iron overload caused by blood transfusion.

In 2010, dispersible tablets were approved for marketing in China!